The Journal of asthma : official journal of the Association for the Care of Asthma · 2025
Montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: cost-utility analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Buendía Jefferson Antonio, Guerrero Patiño Diana, Buendia Sanchez Juan Antonio
Аннотация
OBJECTIVE: This study aims to evaluate the cost-utility of Mon and Flu versus Flu monotherapy in children with CVA in Colombia.
MATERIALS: We simulated a hypothetical cohort of 10,000 pediatric patients diagnosed with CVA, reflecting the typical clinical profile in Colombia. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US$5180. This analysis used QALYs and costs from a third-payer perspective over a 5-year time horizon.
RESULTS: The combination of Mon and Flu is not cost-effective since the incremental cost-utility ratio is greater than the willingness to pay per QALY in Colombia (USD 55,547 vs. USD 5180). The cost of Mon has the greatest influence on cost effectiveness, if the cost per dose of Mon 5 mg is less than US$ 0.034, the combination of Mon and Flu will be cost-effective at WTP of US$ 5180.
CONCLUSIONS: The combination of Mon and Flu is not cost-effective for the management of CVA in children in Colombia, given the current WTP threshold. To enhance the cost-effectiveness of this combination therapy, efforts should focus on reducing the price of Mon and further optimizing its clinical use.
MATERIALS: We simulated a hypothetical cohort of 10,000 pediatric patients diagnosed with CVA, reflecting the typical clinical profile in Colombia. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US$5180. This analysis used QALYs and costs from a third-payer perspective over a 5-year time horizon.
RESULTS: The combination of Mon and Flu is not cost-effective since the incremental cost-utility ratio is greater than the willingness to pay per QALY in Colombia (USD 55,547 vs. USD 5180). The cost of Mon has the greatest influence on cost effectiveness, if the cost per dose of Mon 5 mg is less than US$ 0.034, the combination of Mon and Flu will be cost-effective at WTP of US$ 5180.
CONCLUSIONS: The combination of Mon and Flu is not cost-effective for the management of CVA in children in Colombia, given the current WTP threshold. To enhance the cost-effectiveness of this combination therapy, efforts should focus on reducing the price of Mon and further optimizing its clinical use.